Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-04-016980PMID 16917008PMCID PMC1895445
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.

  2006cited by this paper
• Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96

  2005cited by this paper
• Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

  2005cited by this paper
• Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.

  2005cited by this paper
• Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells.

  2005cited by this paper
• Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha.

  2004cited by this paper
• IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation1

  2004cited by this paper
• Granulocyte colony‐stimulating factor promotes the generation of regulatory DC through induction of IL‐10 and IFN‐α

  2004cited by this paper
• Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer

  2004cited by this paper
• Advances in biology of multiple myeloma: clinical applications.

  2004cited by this paper
• Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

  2004influential reference
• The First 1000 Dendritic Cell Vaccinees

  2003cited by this paper
• Novel and Detrimental Effects of Lipopolysaccharide on In Vitro Generation of Immature Dendritic Cells: Involvement of Mitogen-Activated Protein Kinase p38 1

  2003cited by this paper
• Dendritic Cell-based Immunotherapy in Multiple Myeloma

  2003cited by this paper
• Dendritic Cells

  2003cited by this paper
• Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.

  2002cited by this paper
• Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

  2002influential reference
• Optimizing dendritic cell‐based immunotherapy in multiple myeloma

  2002cited by this paper
• Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

  2001influential reference
• Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions1

  2001cited by this paper
• IL-6 switches the differentiation of monocytes from dendritic cells to macrophages

  2000cited by this paper
• Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.

  2000cited by this paper
• Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.

  2000cited by this paper
• Idiotypic protein‐pulsed dendritic cell vaccination in multiple myeloma

  1999cited by this paper
• Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma—A Feasibility Study

  1999cited by this paper
• Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

  1999cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites

  1998cited by this paper
• Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.

  1998cited by this paper
• Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4.

  1998cited by this paper
• Dendritic cells: unique leukocyte populations which control the primary immune response.

  1997cited by this paper
• Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells.

  1997cited by this paper
• Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma.

  1997cited by this paper
• Dendritic cells as mediators of tumor‐induced tolerance in metastatic melanoma

  1997cited by this paper
• Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

  1997cited by this paper
• Idiotype‐specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets

  1997cited by this paper
• A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

  1997cited by this paper
• Dendritic Cells: Unique Leukocyte Populations Which Control the Primary

  1997cited by this paper
• Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.

  1996cited by this paper
• Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.

  1996cited by this paper
• Interleukin-6 prevents dexamethasone-induced myeloma cell death.

  1994cited by this paper

• Transforming cancer immunotherapy: Overcoming immunosuppression in tumors via gene silencing techniques based on nanoparticles

  2025cites this paper
• Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms.

  2025cites this paper
• Tumor antigen presentation and the associated signal transduction during carcinogenesis.

  2024cites this paper
• Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment

  2024cites this paper
• The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

  2023cites this paper
• Single‐cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage‐targeted strategy in multiple myeloma

  2023cites this paper
• Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

  2022cites this paper
• Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy

  2022cites this paper
• The Immune Microenvironment in Multiple Myeloma: Friend or Foe?

  2021cites this paper
• Boosting Immunity against Multiple Myeloma

  2021cites this paper
• Huaier Extractum Promotes Dendritic Cells Maturation and Favors them to Induce Th1 Immune Response: One of the Mechanisms Underlying Its Anti-Tumor Activity

  2020cites this paper
• Levels of Some Cytokines in Iraqi Patients with Multiple Myeloma

  2020cites this paper
• Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

  2020cites this paper
• The non-linearity of RAF-MEK signaling in dendritic cells

  2020cites this paper
• A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade

  2019cites this paper
• Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression

  2019cites this paper
• Unfavourable biological prognostic factors in Multiple Myeloma

  2019cites this paper
• Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy

  2018cites this paper
• miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38

  2017cites this paper
• current as Cells p 38 MAPK in Cross-Presenting Dendritic Peripheral Deletion of CD 8 T Cells Requires and Grégory

  2017cites this paper
• Variation and significance of secretory immunoglobulin A, interleukin 6 and dendritic cells in oral cancer

  2017cites this paper
• Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells

  2017cites this paper
• Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

  2017cites this paper
• Impact of p38 mitogen-activated protein kinase inhibition on immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.

  2016cites this paper
• Cell Signaling Pathways That Regulate Antigen Presentation

  2016cites this paper
• High glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/β-catenin and p38 MAPK.

  2016cites this paper
• Cell Signaling Pathways that Regulate Ag Presentation

  2016cites this paper
• Clinical Study CD 38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFN γ Cytokines and Proliferation

  2015cites this paper
• Clinical perspectives in cancer vaccines for hematological diseases

  2015cites this paper
• Tumor cell p38 MAPK: A trigger of cancer bone osteolysis.

  2015cites this paper
• Vaccination of multiple myeloma: Current strategies and future prospects.

  2015cites this paper
• Immune suppression in multiple myeloma : strategies to overcome NK cell inhibition

  2014cites this paper
• Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway

  2014cites this paper
• Glycogen Synthase Kinase-3β as a key regulator of human dendritic cell development and suppression

  2014cites this paper
• General introduction: targeting myeloid suppression in cancer immunotherapy

  2014cites this paper
• Cellular immunotherapy in multiple myeloma: lessons from preclinical models.

  2014cites this paper
• p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression

  2014cites this paper
• Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

  2013cites this paper
• Defining Multiple Myeloma as a Target for DNA Vaccines

  2013cites this paper
• Cellular Mechanisms of Multiple Myeloma Bone Disease

  2013cites this paper
• Running title: Role of RAR 2 in multiple myeloma

  2013cites this paper
• Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen

  2013cites this paper
• Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules

  2013cites this paper
• Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.

  2013cites this paper
• Microglial Regulation by Astrocytes: Effect on CD40 Surface Expression and Its Consequences for Dendritic Cell Maturation

  2013cites this paper
• Astrocytes inhibit microglial surface expression of dendritic cell‐related co‐stimulatory molecules through a contact‐mediated process

  2013cites this paper
• Dendritic Cell Vaccination, Immune Regulation, and Clinical Outcomes in Ovarian Cancer

  2013cites this paper
• CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFNγ Cytokines and Proliferation

  2013cites this paper
• The Dark Side of Dendritic Cells: Development and Exploitation of Tolerogenic Activity That Favor Tumor Outgrowth and Immune Escape

  2013cites this paper
• Signaling of Tumor-Induced Immunosuppression of Dendritic Cells

  2013cites this paper
• Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy

  2013cites this paper
• Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous T-cells in patients with MDS.

  2013cites this paper
• Advances in Biology and Therapy of Multiple Myeloma

  2013cites this paper
• p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.

  2012cites this paper
• Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?

  2012influential citation
• Tumor associated regulatory dendritic cells.

  2012cites this paper
• Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma

  2012cites this paper
• Cellular immunotherapy using dendritic cells against multiple myeloma

  2012cites this paper
• Tumor-mediated inhibition of human dendritic cell differentiation and function is consistently counteracted by combined p38 MAPK and STAT3 inhibition

  2012cites this paper
• Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions

  2012cites this paper
• Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.

  2012cites this paper
• Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

  2012cites this paper
• Microenvironment and Immunology p 38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

  2012cites this paper
• Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate® P/Humate-P®)

  2012cites this paper
• Immunology and immunotherapeutic approaches in multiple myeloma.

  2011cites this paper
• Dendritic cell vaccination against ovarian cancer – tipping the Treg/TH17 balance to therapeutic advantage?

  2011cites this paper
• Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins

  2011cites this paper
• Cellular therapy to treat haematological and other malignancies: progress and pitfalls

  2011cites this paper
• Bystander inhibition of dendritic cell differentiation by Mycobacterium tuberculosis‐induced IL‐10

  2011cites this paper
• Inflammatory mediators hold the key to dendritic cell suppression and tumor progression.

  2011cites this paper
• Comparison of immunologic outcomes of laparoscopic vs open approaches in clinical stage III colorectal cancer

  2010cites this paper
• Avaliação da transfecção de células dendríticas com RNA tumoral como estratégia para indução de imunidade específica em pacientes com leucemia linfóide crônica.

  2010cites this paper
• Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

  2010cites this paper
• Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells

  2010cites this paper
• Role of mitogen-activated protein kinase and PI3K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of T H-responses.

  2010influential citation
• Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer

  2010cites this paper
• Dendritic Cell Differentiation Blocked by Primary Effusion Lymphoma-Released Factors is Partially Restored by Inhibition of P38 MAPK

  2010cites this paper
• Dendritic cells, T-cells and their possible role in the treatment of leukaemia and lymphoma.

  2010cites this paper
• Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy.

  2010cites this paper
• Cellular immunotherapy for ovarian cancer

  2009cites this paper
• Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma

  2009cites this paper
• Signaling Pathways Mediating Dendritic Cell Dysfunction in Cancer

  2009influential citation
• Dendritic cells in cancer

  2009cites this paper
• Progress in the use of immunotherapy to treat uterine cervical cancer.

  2009cites this paper
• The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma.

  2009cites this paper
• RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.

  2009cites this paper
• Progress in the use of Immunotherapy to Treat Uterine Cervical Cancer

  2009cites this paper
• RAR (cid:1) 2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma

  2009cites this paper
• Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

  2009cites this paper
• Migration of dendritic cell subsets and their precursors.

  2008cites this paper
• Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.

  2008cites this paper
• Tumor-induced modulation of dendritic cell function.

  2008cites this paper
• Rebuilding immunity in cancer patients.

  2008cites this paper
• Tumour‐mediated disruption of dendritic cell function: Inhibiting the MEK1/2‐p44/42 axis restores IL‐12 production and Th1‐generation

  2008cites this paper
• Toll-like receptors: lessons to learn from normal and malignant human B cells.

  2008cites this paper
• Immunoglobulin free light chains: new insights in mast cell activation and immunology

  2007cites this paper
• Multiple Myeloma Tumor Burden, and Increases Survival in Murine Models of the Development of Osteolytic Bone Disease, Reduces Mitogen-Activated Protein Kinase Prevents α Inhibition of p38

  2007cites this paper
• Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System

  2007cites this paper
• IdiotypeVaccination Strategies in Myeloma : How to Overcome a Dysfunctional Immune System 55

  2007cites this paper
• PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.

  2007cites this paper